Non-Surgical Therapeutic Strategies for Non-Melanoma Skin Cancers

被引:0
作者
Qingyu Zeng
Chengqian Chen
Diyan Chen
Guolong Zhang
Xiuli Wang
机构
[1] School of Medicine,Institute of Photomedicine, Shanghai Skin Disease Hospital
[2] Tongji University,undefined
来源
Current Treatment Options in Oncology | 2023年 / 24卷
关键词
Non-melanoma skin cancer; Basal cell carcinoma; Squamous cell carcinoma; Non-surgical therapy; Photodynamic therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Non-melanoma skin cancer (NMSC) is a globally prevalent skin disease, with basal cell carcinoma and squamous cell carcinoma accounting for 99% of NMSC cases. While surgical excision is the most common approach, numerous non-surgical therapies have rapidly advanced in recent years. In cases of low-risk NMSC, alongside surgical excision, priority should be given to physical therapy and photodynamic therapy. Physical therapy modalities, exemplified by electrodessication and curettage, emerge as safe and efficacious alternatives. In juxtaposition, photodynamic therapy, albeit relatively more costly, assumes preference for patients exhibiting heightened cosmetic concerns owing to the scarring risks inherent to physical therapy and surgical excision. Notably, the combination of curettage and photodynamic therapy has exhibited remarkable efficacy in the treatment of nodular basal cell carcinoma. Additionally, for elderly patients who may be intolerant to stimulation, modified photodynamic therapy offers an almost painless option. When surgery is unavoidable, photodynamic therapy can be a valuable adjunct, allowing for a more conservative surgical approach, either before or after the procedure. Radiotherapy holds a prominent role in comprehensive treatment strategies, especially for patients ineligible for surgical intervention or those with lesions precluding further surgical measures. In cases of NMSC exhibiting perineural invasion or lymphovascular involvement, adjunctive radiotherapy is advised; however, potential adverse effects necessitate careful consideration. For advanced NMSC cases where surgery and physical therapy fall short, immunotherapy provide viable solutions. Systemic therapy employing Hedgehog pathway inhibitors can be considered for patients with distant metastatic basal cell carcinoma, despite its low incidence, or individuals with locally advanced lesions who are not surgical candidates, or those encountering recurrences after resection and radiotherapy. However, close monitoring of disease progression and adverse reactions is crucial. In this evolving landscape of NMSC treatment, personalized and multidisciplinary approaches are key, ensuring optimal outcomes while prioritizing patient safety and satisfaction.
引用
收藏
页码:1978 / 1993
页数:15
相关论文
共 245 条
[1]  
Tanese K(2019)Updates on the Systemic treatment of advanced non-melanoma skin cancer Front Med (Lausanne) 6 160-3695
[2]  
Nakamura Y(2022)Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years BMC Cancer 22 836-844
[3]  
Hirai I(2017)A network meta-analysis of non-melanoma skin cancer (NMSC) treatments: efficacy and safety assessment J Cell Biochem 118 3686-557
[4]  
Funakoshi T(2023)Keratinocytic skin cancers-Update on the molecular biology Cancer 129 836-269
[5]  
Hu W(2022)Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: a systematic review of the literature Int J Dermatol 61 548-30
[6]  
Fang L(2022)Basal cell carcinoma: An updated review of pathogenesis and treatment options Dermatol Ther 35 e15501-2079
[7]  
Ni R(2021)Cutaneous cancer biology Otolaryngol Clin North Am 54 259-131
[8]  
Zhang H(2017)Dermoscopy, confocal microscopy and other non-invasive tools for the diagnosis of non-melanoma skin cancers and other skin conditions Acta Derm Venereol. Suppl 218 22-65
[9]  
Pan G(2015)Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version J Eur Acad Dermatol Venereol 29 2069-600
[10]  
Lv R(2023)Swiss recommendations for cutaneous basal cell carcinoma Dermatology 239 122-1267